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ABSTRACT
Introduction: Ensuring that patients receive care that
is consistent with their goals and values is a critical
component of high-quality care. This article describes
the protocol for a cluster randomised controlled trial of
a multicomponent, structured communication
intervention.
Methods and analysis: Patients with advanced,
incurable cancer and life expectancy of <12 months will
participate together with their surrogate. Clinicians are
enrolled and randomised either to usual care or the
intervention. The Serious Illness Care Program is a
multicomponent, structured communication
intervention designed to identify patients, train
clinicians to use a structured guide for advanced care
planning discussion with patients, ‘trigger’ clinicians to
have conversations, prepare patients and families for
the conversation, and document outcomes of the
discussion in a structured format in the electronic
medical record. Clinician satisfaction with the
intervention, confidence and attitudes will be assessed
before and after the intervention. Self-report data will
be collected from patients and surrogates
approximately every 2 months up to 2 years or until
the patient’s death; patient medical records will be
examined at the close of the study. Analyses will
examine the impact of the intervention on the patient
receipt of goal-concordant care, and peacefulness at
the end of life. Secondary outcomes include patient
anxiety, depression, quality of life, therapeutic alliance,
quality of communication, and quality of dying and
death. Key process measures include frequency, timing
and quality of documented conversations.
Ethics and dissemination: This study was approved
by the Dana-Farber Cancer Institute Institutional Review
Board. Results will be reported in peer-reviewed
publications and conference presentations.
Trial registration number: Protocol identifier
NCT01786811; Pre-results.
INTRODUCTION
Ensuring that patients receive care that is
consistent with their goals and values is a
critical component of high-quality care.1
Early conversations about advance care plan-
ning (ACP) with seriously ill patients have
been associated with better outcomes for
patients and families.2–4 However, multiple
deﬁcits in the timing and content of these
discussions have been described. Discussions
occur too late, when patients are in crisis or
unable to make decisions for themselves, or
clinicians who know the patient are not avail-
able.5–7 Even though most patients want to
know about their prognosis, such informa-
tion is often not shared,8 9 leading to poorly
informed decisions. Furthermore, contrary
to expert recommendations,1 physicians tend
to focus these critical conversations on
choices about procedures (eg, resuscitation
or feeding tube insertion) rather than on
the goals, values and wishes that form the
basis of an informed patient’s decisions.
Clinicians are underprepared and under-
trained to conduct high-quality end-of-life
conversations,10 and tend to avoid them.11
Several studies of physicians in the UK,12 the
USA,13 and in an international palliative care
training programme14 15 demonstrate that
communication skills instruction pro-
grammes are effective,16 with participants
showing sustained improvement in patient-
centered communication skills, including sig-
niﬁcant improvement in responses to
patients’ emotional cues.12 Interactive, case-
based learning sessions with communication
skills practice are the most effective;17
however, most often, these training pro-
grammes have been intensive, multiday
off-site retreats which are not always feasible
for busy clinicians in practice.
One proposed solution to deﬁcits in ACP
and end-of-life discussions is for palliative
care clinicians, who are trained to conduct
such conversations, to see all seriously ill
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patients. Early palliative care intervention, the primary
focus of which is communication,18 with ambulatory
patients with non-small cell lung cancer has been
demonstrated to improve quality of life, mood and
survival, and to reduce aggressiveness of care and
hospital length of stay.4 While palliative care physicians
are an excellent resource for conducting/assisting with
end-of-life conversations, there is already a shortage of
approximately 11 000 palliative medicine physicians
for hospices and hospital-based palliative care pro-
grammes;19 this workforce shortage is only expected to
increase with future demographic changes. It is unlikely
that this care model will be scalable.20 Thus, other
approaches are needed, to engage non-palliative care
physicians in integrating basic elements of palliative care,
such as ACP, in the care of patients with serious illnesses.
We have developed, piloted and reﬁned a multicom-
ponent Serious Illness Care Program (SICP) to improve
conversations about values and goals for patients with
serious illnesses. The goals of this programme are to
train and support oncology clinicians in integrating best
practices in ACP in the care of their patients, to optimise
the alignment between patient goals and the medical
care they receive, and to enhance quality of life and
peacefulness throughout the late stages of illness. We
describe the steps taken in developing the programme,
including review of the evidence about the effectiveness
of ACP discussions,21 22 pilot work with oncologists to
improve their ACP practices, engagement of a national
advisory board, and development and pilot-testing of a
structured approach to these conversations in the form
of a seven-item Serious Illness Conversation Guide
(SICG) for clinicians and patients. Then, we describe
the research protocol: setting, recruitment, measure-
ments, design of the intervention, timing of assessments,
data analysis and collection, and planned analyses and
dissemination.
Literature review
We conducted and published an extensive literature
review of the evidence about early goals-of-care discus-
sions.21 These discussions were found to be associated
with better quality of life, reduced utilisation of
non-beneﬁcial medical care near death, enhanced
goal-consistent care, positive family outcomes and
reduced costs. Existing evidence does not support the
commonly held belief that communication about
end-of-life issues increases patient distress. The review
also described best practices in conversations about
serious illness care goals, and offered guidance to clini-
cians and healthcare systems on following a systematic
approach to quality and timing of such communication
to assure that each patient has a personalised serious
illness care plan.
Pilot work
To begin understanding how the physicians in our insti-
tution actually conduct ACP discussions, we asked
oncologists in the Gastrointestinal Oncology and
Neuro-oncology centres at the Dana-Farber Cancer
Institute (DFCI) to conduct values and goals discussions
with their patients with pancreatic cancer or glioblast-
oma multiforme as part of an institutional quality
improvement initiative. We evaluated clinical documen-
tation before and after education where we introduced
clinicians to an ACP module in the electronic medical
record (EMR) intended to simplify tracking of patient
values and goals. The proportion of patients whose phys-
ician documented their values and goals was low (<5%)
before the intervention, and the norm (>90%) after the
intervention. Following this pilot initiative, we solicited
feedback from the clinicians with a structured interview
about their experiences in conducting and documenting
these discussions. This feedback later informed the
development of our conversation guide and training
programme.
Consultation with National Advisory Group
Early in the project, we gathered a national panel of
experts for an Advisory Group for the SICP. Members
included palliative care specialists, general internists, car-
diologists, oncologists, paediatricians, surgeons and
patients. Some members had extensive expertise in
end-of-life communication skills and ACP; others were
representative clinicians and patients who would be
using the intervention. The purpose of the meeting was
to discuss key elements of agreement and disagreement
about best practices in serious illness communication, to
elicit feedback about a proposed intervention, and to
obtain input on our research design. Prior to the
meeting, all members received an extensive background
document, including a literature review.
Development of the SICP materials
Building on our literature review and pilot work, we
developed a systematic approach to integrate best prac-
tices in outpatient care for patients with serious illnesses,
and proposed a structured format to guide the discus-
sions—the novel seven-item SICG (ﬁgure 1). This guide
addresses eliciting illness understanding, eliciting
decision-making preferences, sharing prognostic infor-
mation according to preferences, understanding goals
and fears, exploring views on trade-offs and impaired
function, and wishes for family involvement. In addition
to the SICG, designed for clinicians to use in outpatient
encounters with their patients, we developed a letter to
give patients before the visit to help them prepare for
the discussion, and a family communication guide to
send home with patients after the discussion to aid in
discussing their values and goals with their family. The
family guide follows the same general structure as the
SICG, but in the patient’s voice.
Patient input
We sought feedback from the DFCI Patient and Family
Advisory Council about our materials (SICG, family
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guide, pre-visit letter, etc) through a series of meetings.
The Patient and Family Advisory Council consists of
patients, family members, executive leaders and provi-
ders partnering to improve hospital programmes, pol-
icies and the overall quality of care of the DFCI. In
addition, we worked with a marketing ﬁrm (Hill
Holliday, http://www.hhcc.com) that conducted patient,
family and clinician focus groups to determine accept-
ability of terminology, wording and format; we used
these data to reﬁne our materials.
Pilot testing the guide
We piloted the SICG with 26 practitioners—physicians
from multiple specialties including internal medicine,
oncology, nephrology, critical care, surgery and neur-
ology, as well as nurse practitioners (NPs) and physi-
cian’s assistants. Clinicians were given a brief overview of
the project and were trained to use the conversation
guide. They were then observed and audio-recorded as
they conducted a discussion with a trained actor serving
as a standardised patient. Clinicians ﬁrst followed their
usual approach to an end-of-life conversation, then were
asked to use the guide’s structured format. We then
debriefed with the clinicians about the wording, order,
structure and acceptability of the guide, as well as any
other feedback. We made changes based on clinicians’
suggestions. We used the newly edited version of the
SICG for the next round of interviews. We continued
this cycle (approximately 3 clinicians per cycle) until
our participants suggested no more signiﬁcant changes
to the guide (eight cycles).
METHODS AND ANALYSIS
Trial design
The study is a prospective, cluster-randomised controlled
trial of a quality-improvement intervention. We enrol
oncology physicians, NPs, physician assistants (PAs) and
ambulatory patients with cancer and their identiﬁed sur-
rogates. We are conducting the study at the DFCI, and at
two afﬁliated satellite clinics (Dana-Farber at Milford
Regional Medical Center, and Dana-Farber at South
Figure 1 Serious Illness
Conversation Guide.
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Shore Hospital). DFCI is a National Cancer Institute
designated comprehensive cancer centre located in
Boston, Massachusetts and part of the National
Comprehensive Cancer Network. The DFCI is organised
into ‘disease centres’, each of which focuses on a spe-
ciﬁc class of illnesses. Clinicians from these disease
centres, except for those in gynecologic oncology
department, where there is another ongoing trial that
overlaps with the objectives of this one, were asked to
volunteer for the study. Among the clinician volunteers
(including physicians, NPs and PAs), half were rando-
mised into the intervention group, and the other half
into a control group. Physicians, NPs and PAs in the
intervention group were trained in using the SICG and
received ongoing coaching from the study team. The
control group provides usual care. In addition, because
we hypothesise that volunteer clinicians would be differ-
ent from non-volunteer clinicians and would therefore
have patients with different outcomes than the patients
of their volunteer-colleagues, we are enrolling the
patients of a third group of clinicians who did not volun-
teer for the study and who also provide usual care (see
ﬁgure 2 for the study design).
Participant recruitment
Clinicians
All medical oncologists who see patients at least one half
day a week are eligible to participate. Study staff
recruited and enrolled clinicians at disease centre meet-
ings, by email and in person. Oncologists who declined
participation received an email notifying them that their
patients will be invited to participate. All volunteers
received a $150 gift card.
NPs and PAs were also enrolled in the study. They
were recruited and consented in the same fashion as the
physicians, and also received a $150 gift card for enrol-
ment. In order to minimise the possibility of contamin-
ation if a patient sees clinicians from both arms of the
study, enrolled NPs and PAs were enrolled in the study
arm of their collaborating physicians. If an NP or PA
works with both intervention arm physicians and either
control arm or non-enrolled physicians, they were
excluded from the study.
Patients
Only patients receiving their ongoing primary oncology
care at DFCI are eligible for participation in the study.
Enrolment criteria include: age >18 years,
English-speaking, able to consent and complete periodic
surveys, and also to identify a friend or family member
willing to answer surveys. Since the trial relies intensively
on the clinician’s communication skills about a culturally
complex topic, we feel that relying on interpreters, who
do not have experience with these conversations, and
who have been shown to be unreliable translators of
emotionally difﬁcult material,23 24 might expose patients
and their families to greater distress without separate
testing to determine suitability. Therefore, all
non-English-speaking patients were excluded from the
study (see ﬁgure 3 for a visual representation of
recruitment).
Figure 2 Research design.
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Surrogates
Patients identify a surrogate—a friend or family member
—who is able to participate in the study. The friend or
family member can consent remotely and is not
required to attend clinic appointments with the patient
but is asked to answer surveys. The friend or family
member is required to be over 18, speak English, and
have the ability to provide consent. If the identiﬁed sur-
rogate does not wish to participate, then the patient is
asked to suggest another individual. If no surrogate is
identiﬁed, then the patient is ineligible for the study
(see ﬁgure 3 for a visual representation of recruitment).
Intervention
The intervention is a multicomponent, structured com-
munication intervention designed to (1) identify
patients at high risk of death in the next year; (2) train
clinicians to use the SICG to structure advanced care
planning discussion with patients; (3) ‘trigger’ the oncol-
ogy clinicians to have conversations using the guide with
enrolled patients; (4) prepare patients for the conversa-
tion by providing them with a letter encouraging them
to think about some of the topics raised in the Guide;
(5) guide clinicians in conducting values and goals con-
versations; (6) document outcomes of the discussion in
a structured format in the EMR and (7) provide patients
with a Family Communication Guide to help them con-
tinue the discussion at home with their loved ones.
Population identification
To identify eligible patients, we use a ‘No’ answer to the
question, ‘Would you be surprised if this patient died in
the next year?’, if the patient meets other study require-
ments. The ‘surprise question’ is a validated single-item
method for identifying patients at high risk of dying
within a year among advanced cancer and dialysis
patients.25 26 A physician answering ‘No’ to the question
‘Would I be surprised if this patient died in the next
year?’ confers an HR of death of 7.9 for patients with
cancer.26 Every patient identiﬁed by a clinician with a
‘No’ response on the surprise question is invited to par-
ticipate in the study by a letter with an opt-out card. If
the opt-out card is not returned, a follow-up phone call
is conducted to invite participation.
Figure 3 Patient/family
recruitment and assessment.
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Recruitment in the neuro-oncology clinic is conducted
using the surprise question and via review of ICD-9
codes to identify any patients with a diagnosis of a
cancer that has a high mortality risk (eg, glioblastoma
multiforme); those patients are deemed eligible to be
approached for consent after their fourth clinic visit.
Training and coaching programme
In order to minimise time commitment for clinicians,
we designed a 2.5 h training programme for interven-
tion clinicians to develop their competencies in using
the SICG21 (table 1). The training begins with a brief
didactic session (<30 min) on the evidence base for ACP
discussions. A demonstration and discussion of the use
of the SICG (approximately 30 min) are followed by
individualised practice by all participants, using role-
plays with personalised feedback from attending
palliative care physicians (more than 60 min). Training
sessions include 6–10 participants per session. Trained
actors serve as standardised patients for both the dem-
onstration and role-play. Clinicians learn how to intro-
duce the conversation, including: (1) orienting patients
to the conversation, (2) asking for permission to discuss
desires for future care, (3) reassuring patients about
continued treatment, (4) stating support for the patient
and family and (5) emphasising that no decisions have
to be made during the initial discussion. At the end of
their patient conversations, clinicians are instructed to
summarise and conﬁrm the content of the conversation,
and provide patients with a Family Communication
Guide (ﬁgure 4) that can encourage further discussion
of issues with family members. All intervention clinicians
receive the Clinician Reference Guide, which sum-
marises information provided in the training and offers
guidance on challenging scenarios. The training con-
cludes with a tutorial for clinicians on how to access and
complete the EMR documentation module. Finding the
time to conduct a conversation was a signiﬁcant issue
discussed in the training session. Clinicians were given
leeway as to how to ﬁt the conversation into their
workday. We allowed clinicians to split the conversation
between several visits, that is, that one or two questions
would be addressed at each visit. We advised clinicians
that we would continue to remind them to conduct the
conversation until all questions were complete in the
EMR documentation module.
After each intervention clinician’s ﬁrst SICG conversa-
tion with a patient, a physician member of the SICP
team reviews the conversation, elicits feedback from the
clinician, and offers suggestions. Intervention clinicians
can also contact the SICP team in person, by paging and
telephone or by email to discuss their conversations.
Group or individual coaching sessions on difﬁculties
with these conversations are similarly available from the
SICP physicians, both for routine and challenging cases.
In these sessions, the coach asks clinicians to identify
Table 1 Goals of the Serious Illness Care Training Program
By the end of the programme, learners will be able to demonstrate
Goal Outcome
1. Communication skills
Use of silence, facilitating patient talk ▸ Allows silence before responding when patient is taking in
information or expressing emotion
▸ Patient speaks >50% of time
Acknowledging and responding to patient/family
emotion
▸ Acknowledges difficult emotions during discussion
▸ Responds to emotion with empathic comment or further
exploration
▸ Avoids using information or premature reassurance to respond to
emotion
Eliciting patient concerns ▸ Encourages patient to express fears, worries, other concerns
Assessing patient receptivity ▸ Accurately assesses patient’s receptivity to receiving new
information and considering other options for treatment
Recognising appropriate time for exploration and for
making a recommendation
▸ Initiates conversation early in the course of illness, and when
prompted by disease progression or other clinical changes
▸ Makes a recommendation based on an accurate assessment of
patient receptivity
Identifying key challenging scenarios in using the
SICG, and strategies for addressing them
▸ Describes concrete strategies for dealing with crying, anger,
denial, and avoidance
Use of follow-up questions to further explore
unclear or limited patient responses
▸ Asks follow-up questions when patient does not provide a full or
complete answer to SICG question
2. Mastery of SICG
Effective use of SICG ▸ Clinician completes all elements of SICG
Shares prognosis (as desired by patient) ▸ Gives prognosis in a range (days to weeks, weeks to months, etc),
with acknowledgement of uncertainty
Documentation in ACP module ▸ Documents critical information for colleagues in ACP module
ACP, advance care planning; SICG, Serious Illness Conversation Guide.
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problem areas and then facilitates discussion of
approaches to the challenges presented, including use
of role-play.
Triggering
Trained clinicians are triggered by the research staff to
have the SICG discussion with enrolled patients in an
upcoming visit in two ways: (1) an email is sent the day
before the visit notifying the clinician that the study
patient is due for an SICG conversation and (2) on the
day of the visit, a packet with the study materials (SICG,
Family Guide, and a Post-Conversation form) is placed
with the face sheet that is given to clinicians before each
patient visit. We collect data on the number of triggers it
takes to complete the intended SICG conversations.
Pre-visit letter
In order to activate patients and ensure they are pre-
pared for the conversation, intervention patients receive
a pre-visit letter (ﬁgure 5), which introduces the SICG
topics to consider prior to their conversation with their
clinician.
Serious Illness Conversation Guide
The seven key elements that should be addressed with
patients are shown in ﬁgure 1. These include: illness
understanding, decision-making and information prefer-
ences, prognostic disclosure, patient goals and fears,
views on acceptable function and trade-offs, and desires
for family involvement.
Electronic medical record module documentation
We developed a structured format for documentation
that aligns with the seven items of the SICG in the ACP
module of our EMR (ﬁgure 6). The module is designed
to remind clinicians of the key elements of the discus-
sion, to ease the burden of documentation, and to allow
other clinicians easy access to the information elicited
from the conversation. Each SICG question is mirrored
in the module with a free text box and checkboxes in
which to record responses. This module offers a single
location for all information related to patient values and
preferences, and allows interdisciplinary team members
to review, enter and track preferences over time. All
entries automatically include identiﬁcation of the date,
time and author of the documentation.
Family guide
After the conversation, the clinician gives patients a
Family Guide that suggests an approach for discussing
their illness and care preferences with their family.
Outcome data collection
The primary outcomes of the trial are patient receipt of
goal-concordant care, and peacefulness at the end of
life. Key process measures are acceptability of the SICG
conversation to patients, acceptability of training to clini-
cians, number of triggers required to complete SICG,
and frequency, timing, and quality of documentation of
goals of care discussion. Secondary outcomes include:
anxiety, depression, quality of life, therapeutic alliance,
quality of communication, and quality of dying and
death. We describe below how these outcomes will be
Figure 4 Family communication
guide (front page only).
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measured. We plan to report outcomes in two phases:
phase I will include key process measures and secondary
outcomes and phase II will include the primary out-
comes plus late secondary outcomes.
Timing of assessments
All study patients receive a baseline survey and then are
surveyed every 2 months. For patients in the intervention
arm, 1 week after the SICG conversation is complete,
the patient is surveyed to assess their perception of the
conversation, including its acceptability. Control patients
are administered a parallel survey 2 months after enrol-
ment, around the same time when patients in the inter-
vention group would be likely to have an SICG
conversation, based on pilot data prior to the
randomised study. The control patients are asked about
the number and content of their ACP or end-of-life dis-
cussions with their clinicians and families.
Patient measures
Table 2 lists the questionnaires and timing of administra-
tion for patients. Patients complete questionnaires by
email, postal mail or phone. Demographic information
includes age, gender, education, oncological disease,
ethnicity and religion.
Surrogate measures
Table 3 lists the questionnaires and timing of administra-
tion for surrogates. We collect surrogate demographics
including age, gender, education, ethnicity and religion.
Figure 5 Pre-visit letter for patients.
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Friends/family members are surveyed every 2 months
about the frequency and quality of communication with
the patient about ACP and about their perception of the
patient’s life priorities using the Family Perception
Scale. Six to 12 weeks after the patient’s death, a social
worker interviews the family member/friend on the
phone using a modiﬁed form of the Quality of Dying
and Death instrument (QODD).27–29 Additional ques-
tions from FAMCARE that address issues not covered in
the QODD are included. The FAMCARE scale is a vali-
dated instrument to measure family satisfaction with
advanced cancer care and can be administered to family
members after the patient’s death.30 We also collect the
friend/family member’s perceptions of the patient’s
achievement of self-identiﬁed goals using an adaptation
of the Life Priorities measure. Prior to conducting the
interview, which is audio-recorded, the social workers
received a 1 h training from a bereavement specialist.
Clinician measures
Table 4 lists the questionnaires and timing of their
administration for clinicians. At baseline, we record
gender, profession (MD, NP or PA), disease centre, per-
centage clinical time, and years in practice, and adminis-
ter questionnaires on clinician conﬁdence in and
attitudes about end-of-life conversations. The same ques-
tionnaire is administered following SICG training and
will be administered at the conclusion of the study. Each
time after a clinician is triggered to have a conversation,
we ask them to complete a Post-Conversation
Questionnaire. Clinicians provide information about
prognostic communication, the length of the discussion,
and whether they deviated from the SICG for any
reason. For clinicians and patients who agree (a separate
item on the consent form), a subset of conversations are
audio-recorded. If the conversation did not take place,
the same questionnaire asks clinicians to report their
Figure 6 Electronic module of the Serious Illness Conversation Guide. (c) 2015 Epic Systems Corporation. Used with
permission.
Table 2 Patient measures and timing of administration
Timing of administration
Domain Measurement tool Validated
Base
line
After first
conversation or
2 months after
enrolment
Every
2 months
Demographics ✓ ✓
Patient acceptability ‘Patient Acceptability’ ✓
Quality of life SF-12 ✓ ✓ ✓ ✓
Peacefulness PEACE Questionnaire ✓ ✓ ✓ ✓
Life priorities Purpose designed ✓ ✓
Goals of treatment Dichotomized choice question from
SUPPORT study
✓ ✓ ✓ ✓
Therapeutic alliance Modified Human Connection Scale ✓ ✓ ✓ ✓
Anxiety Generalized Anxiety Disorder (GAD 7) ✓ ✓ ✓ ✓
Depression Patient Health Questionnaire (PHQ-9) ✓ ✓ ✓ ✓
Quality of
communication
Quality of Communication with
Clinician-Engelberg
✓ ✓ ✓ ✓
‘Quality of Communication with Family’ ✓ ✓ ✓
Bernacki R, et al. BMJ Open 2015;5:e009032. doi:10.1136/bmjopen-2015-009032 9
Open Access
reasons for deferring the discussion. Clinician data also
include how often we are emailed and paged for coach-
ing by clinicians, as well as the number of one-on-one or
group coaching sessions attended.
Process measures
Table 5 describes the process measures tracked in the
study. We conduct a chart review to assess frequency,
timing, and quality of conversations on patients who die.
We will count the number of intervention and control
patients with goals-of-care conversations documented in
the EMR, the extent and retrievability of documentation
in the EMR (eg, is the information in the Advance Care
Planning Section of the EMR, or included in a progress
or other note). In addition, the timing of conversations
for intervention and control patients will be reported
relative to time of death. Finally, we will count the
number of key elements of goals-of-care discussion
(based on best practices) documented in the EMR.
Evaluation of goal concordance
We could not identify a ‘gold standard’ for measurement
of concordance between the patient’s wishes and the
care provided at the end of life; validated measures of
this critical construct do not exist.31–36 Thus, we exten-
sively reviewed existing literature on the topic, inter-
viewed patients, and used this information to design a
‘Life Priorities’ survey for patients and a ‘Family
Perceptions’ survey for identiﬁed surrogates. The Life
Priorities survey evaluates patient priorities before death
and the extent to which those priorities are subsequently
achieved. The Family Perception survey assesses the
extent to which the identiﬁed surrogate understands the
patient’s priorities while the patient is alive, and the
extent to which those priorities were achieved in the last
week and last 3 months of the patient’s life, and also
asks speciﬁc questions about the care received in the
months, weeks and days before death. The last patient-
reported Life Priorities survey before death will be used
as the primary outcome. We have included two add-
itional validated questions in the patient surveys, and we
will compare these responses to those from our Life
Priorities Scale to evaluate the validity of our measure.37
To determine the extent to which patients receive care
that is consistent with their top life priorities in the last
3 months and last week of life, we will compare the
patient’s top three ranked life priorities to the patient’s
care experience at the end of life using family percep-
tion of patient’s achievement of goals and medical
record review. Using that information and the scoring
system of 0, 1, 2 or 3 corresponding to the number of
these top three goals that are met at the end of life, a
team of independent, blinded physicians will determine
the extent of goal concordance.
Peacefulness
The validated PEACE scale, or the ‘Peace, equanimity
and acceptance in the cancer experience’ scale, will be
used to measure patient peacefulness at the end of life.
The PEACE instrument contains two subscales, ‘Peaceful
acceptance of Illness’ and ‘Struggle with Illness’. The
‘Peaceful acceptance of Illness’ subscale will be used as
the main outcome.38
Secondary outcomes
We examine patient anxiety using the validated
Generalized Anxiety Disorder (GAD-7)39 40 and evaluate
depression using the validated Patient Health
Table 3 Surrogate measures and timing of administration
Timing of administration
Domain Measurement Tool
Base
line
After first
conversation or
2 months after
enrolment
Every
2 months
Eight weeks
after patient
death
Demographics ✓
Quality of
communication
‘Quality of Communication with
Family’
✓ ✓ ✓
Quality of death Quality of Dying and Death (Curtis) ✓
Table 4 Clinician measures and timing of administration
Timing of administration
Domain Measurement tool Base line After training After first conversation End of study
Attitudes Clinician Attitudes Survey ✓ ✓ ✓
Confidence Clinician Confidence Survey ✓ ✓ ✓
Acceptability Clinician Acceptability Survey ✓ ✓
Prognostic evaluation Post-conversation Form After every conversation
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Questionnaire (PHQ-9).41 We measure therapeutic alli-
ance using the Human Connection Scale.42 The Human
Connection Scale is a valid and reliable measure of
therapeutic alliance between patients with advanced
cancer and their physicians.42 We assess patient percep-
tion of the quality of communication with their clin-
ician32 43 using the ‘Quality of Communication’ (QOC)
scale, a 13-item validated questionnaire that measures
the quality of end-of-life communication in two scales: a
six-item ‘general communication skills’ scale and a
seven-item ‘communication about end-of-life care’
scale.44 We measure quality of life and general physical
health function by the SF-12 V2 health survey.45 It con-
sists of 12 items and provides scores for both overall
physical and mental health. We use the Brief R-COPE, a
6-item measure that assesses positive religious (PRC)/
spiritual methods of coping and dealing with life stres-
sors, and negative religious (NRC)/spiritual methods of
coping that are representative of the religious struggle
when dealing with life stressors.46
Sample size
Power calculations were performed for the two primary
aims of the study: comparison of enhanced goal-consistent
care and comparison of the PEACE measure across the
randomised arms. In order to ensure an overall 5% type I
error rate for the two primary aims, we will use a 2.5% type
I error rate for each of the two primary hypotheses. Both
aims are based on patient death; we expect to follow each
patient for at least 1 year from randomisation, or until
death if <1 year from randomisation. The power calcula-
tions below are based on having 200 evaluable patients per
arm. We allow for 6% unevaluability due to patient
dropout, meaning a total of 426 patients (213 per group)
will be accrued at an estimated accrual rate of 200 patients
per year. Given that each patient must be followed for at
least 1 year from randomisation, we expect the study to be
open for at least 3 years.
Primary aim 1
Enhanced goal-consistent care: The outcome for a patient
will be a score of 0, 1, 2 or 3 corresponding to the
number of the top three high priority goals that are met
in the last week and 3 months of life. Based on previous
data, the SD of ‘number of high priority goals met’ is
conservatively estimated to be 1.35, and we expect the
average ‘number of high priority goals met’ to be at
least 0.6 point higher with the SICG (a clinically import-
ant increase based on prior studies). The two arms will
be compared using a robust generalised estimating equa-
tions (GEE) Wilcoxon rank-sum-type score test47 for
ordinal categorical data; this approach does not assume
normality of the outcome, and accounts for a possible
cluster effect of patients within clinician. Using the GEE
Wilcoxon rank-sum score test with a two-sided type I
error rate of 2.5% and 200 evaluable patients per arm,
we have over 80% power to detect an average 0.6 point
higher average score in the SICG arm. In this power cal-
culation, an intracluster (clinician) correlation coefﬁ-
cient (ICC) of approximately 0.1 has been assumed, as
is (conservatively) commonly used in this type of cluster
randomisation study.48
Primary aim 2
PEACE scale: From previous data,38 the SD of the
‘Peaceful acceptance subscale’ is conservatively estimated
to be 3.3 (‘conservatively’, since this is the largest SD
found in Mack et al38), and we expect the average score
to be at least 1.3 points higher with the intervention
(again, a clinically important increase based on prior
studies). The two arms will be compared using the GEE
Wilcoxon rank-sum score test accounting for clustering
of patients within clinician. Using a GEE Wilcoxon
rank-sum score test with a two-sided type I error rate of
2.5% and 200 evaluable patients per arm, we have over
80% power to detect a 1.3-point higher average
‘Peaceful acceptance subscale’ in the intervention arm,
assuming the ICC=0.1.
Interim analysis/early stopping rules
For primary aims 1 and 2, the trial will be monitored for
possible early stopping due to a large intervention effect
using a Haybittle-Peto approach.49 Speciﬁcally, one
interim GEE Wilcoxon rank-sum score test will be per-
formed after approximately 50% of the total patients are
enrolled, which should occur approximately 6 months
after baseline and with 213 patients. In order to stop the
study at this point in favour of the SICG arm, the
p value for GEE Wilcoxon rank-sum score test must be
<0.001. The power calculations above take into account
the possibility of one interim analysis. The stopping rule
for this study will be used as a guideline rather than as a
hard-and-fast rule. Any ﬁnal decision will also consider
Table 5 Process measures: frequency, timing and quality
of conversations
Outcome Measure
Frequency Chart review of outpatient oncology progress
notes to determine the percentage of
intervention and control patients who had
documentation of goals of care before death
Timing Chart review of outpatient oncology progress
notes to determine the timing of the first
documented goals-of-care conversation
before death in intervention and control
patients
Quality Chart review of outpatient oncology
documentation to assess retrievability
(Advance Care Planning Section of EMR vs
progress notes vs other locations) and to
compare the number of key elements
addressed in documented goals of care
conversations in intervention and control
patients
EMR, electronic medical record.
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additional end points such as differences in complica-
tions and process measures. If the ﬁndings of the
interim analysis are in favour of stopping the trial due to
beneﬁcial effect of the SICG, the research study will be
stopped. We note here that we used a simpler conserva-
tive interim analysis approach49 because the less conser-
vative approaches50 require independent increments of
data; however, the data will not likely come to us in inde-
pendent increments because of the cluster randomised
design. Further, as we have chosen a conservative
interim analysis approach, the one interim analysis can
be performed at any time during the study, and the stop-
ping rule of p<0.001 still applies.
Randomisation
The oncologists are stratiﬁed by disease centre or satel-
lite facility. The strata correspond to the disease centres
(breast, gastrointestinal, genitourinary, leukaemia,
lymphoma, thoracic, sarcoma, head & neck,
neuro-oncology) and two satellite facilities. The smallest
disease centre, melanoma, was not randomised because
cross contamination would be likely due to its small size;
it served as a pilot site. Clusters are organisational units
of clinicians within a disease centre; a typical cluster
would have one NP and 2–3 physicians, although the
numbers of particular clinicians vary across disease
centres; randomisation was carried out by cluster.
Within strata, one-half of the clusters were randomised
to the intervention and one-half of the clusters were ran-
domised to standard care. The cluster is randomly
assigned to intervention or control based on a random
number drawn in SAS. The GEE statistical methods
described in the power calculations take into account
the stratiﬁcation (disease centre) and clustering (clini-
cians) variables in the analysis.
Blinding
For the telephone bereavement interviews, social
workers who are not involved in the study conduct the
interviews and are blinded to the study arm of the
patient and surrogate (intervention vs control).
Planned analytic approach
The objective of this study is to evaluate whether, for
patients with cancer, the SICP is better than usual care
at helping patients achieve healthcare goals and quality
of life in the setting of serious illnesses. The design is a
cluster-randomised controlled trial in which patients are
nested within clinician clusters. One-half of the oncology
clinicians are randomised to the SICP and one-half of
the oncology clinicians are randomised to standard care.
Since this is a randomised trial with stratiﬁcation by
disease centre prior to randomisation, we expect the
demographic characteristics and other possible confoun-
ders (age, disease severity, etc) to be similar in the two
groups. However, since randomisation is at the cluster-
level and there are 50 total clusters, there is a slightly
greater chance that characteristics will not balance out
than if randomisation was done at the patient level.
Prior to evaluating the effect of the intervention, the
demographic characteristics of test arms will be com-
pared by the Rao-Scott χ2 (accounting for stratiﬁcation
by disease centre and clustering by oncology clinician)
for discrete variables, and by the GEE Wilcoxon
rank-sum score test for ordered categorical variables and
continuous variables (accounting for stratiﬁcation by
disease centre and clustering by oncology clinician).47 If,
as expected, there are no differences in demographic or
other confounders, the primary outcomes across arms
will be compared using the GEE Wilcoxon rank-sum
score test for ordered categorical variables and continu-
ous variables (accounting for stratiﬁcation by disease
centre and clustering by oncologist).47
If baseline differences are found between the two
arms with respect to important confounders (such as
age, race, comorbidities), the GEE Wilcoxon rank-sum
test will incorporate propensity weights. In particular, to
conduct the propensity score adjustment, we will use a
logistic regression model to calculate the propensity
(probability) of being in the intervention or control
groups based on all possible confounders, and then
weight each participant in the GEE Wilcoxon rank-sum
score test based on the inverse propensity of being in
one of the two treatment groups.51 This study evaluates
the impact of the entire intervention, and will not
address which components of this multicomponent pro-
gramme are effective.
ETHICS AND DISSEMINATION
Ethical review
All participants provide informed consent and may with-
draw at any time without impacting their treatment or rela-
tionship with their clinical team. An approved protocol to
monitor for adverse events is followed and additional
support for patients with symptoms of psychological dis-
tress is available through the Palliative Care and
Psychosocial Oncology clinical programmes. Additionally,
we monitor patient responses to the PHQ-9 measure of
depression whenever these responses are collected. If the
patient answers ‘More than half the days’ or ‘Nearly every
day’ to the question, ‘Thoughts that you would be better
off dead, or of hurting yourself’, or if the patient responses
indicate severe depression (PHQ-9 score of 20 or greater),
we immediately notify the patient’s NP or physician by
pager or phone. We also monitor the GAD-7 measure of
anxiety and the pain score to screen for the following indi-
cators of patient distress: severe anxiety (GAD-7 score of 15
or greater), and severe pain (level of 8 or greater). When
any of these conditions are met, we notify the patient’s NP
or physician by email within 24 h.
Relevance and dissemination
The design of the SICP addresses critical deﬁciencies in
the conduct of end-of-life conversations. The SICP, if
successful, provides a simple, scalable structure to
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support oncology physicians, NPs and PAs in conducting
state-of-the-art serious illness conversations with a broad
array of oncology outpatients at a high risk of dying
within a year. We do not know the generalisability to
other populations of seriously ill patients, such as those
with congestive heart failure or chronic obstructive pul-
monary disease. Likewise, we are limited to analysing the
data of the patients who agreed to participate in the
trial and cannot characterise patients who opted out,
who might be less willing to discuss these issues.
The Conversation Guide, while not comprehensive,
has been designed to balance brevity to enhance scal-
ability, while at the same time addressing the issues that
matter most to patients. The length of the clinician
training (2.5 h) was chosen as an acceptable amount of
time that would be feasible for many healthcare systems
to adopt, if successful. We anticipate that clinician train-
ing will improve the quality of these conversations, and
that enhancing clinician conﬁdence, knowledge, and
skill, the lack of which are known barriers to ACP, will
increase the frequency of effective serious illness conver-
sations. By triggering the conversations early in the
course of the illness, our goal is for patients with serious
illness and their families to be able to consider decisions
about their lives and choices about medical care with
adequate time for reﬂection and discussion. The design
of the EMR module creates a repository of information
about patient values and goals, reinforces use of the
SICG, reduces time needed to record information, and
communicates patient goals and values in a readily
accessible place in the EMR that is easily retrievable by
other clinicians, especially in an emergency.
Our ultimate aim is to determine if we can provide a
proven means for transforming end-of-life care through
an innovative model that enables patients with serious
illness and non-palliative care clinicians to discuss prefer-
ences for end-of-life care more often, earlier, and more
effectively. We believe that developing scalable models
for improving serious illness conversations will contrib-
ute to better alignment of healthcare with the prefer-
ences of oncology patients, and eventual extension to
other patient populations and care settings.
Author affiliations
1Harvard Medical School, Boston, Massachusetts, USA
2Department of Psychosocial Oncology and Palliative Care, Dana-Farber
Cancer Institute, Boston, Massachusetts, USA
3Ariadne Labs at Brigham and Women’s Hospital and the Harvard T. H. Chan
School of Public Health, Boston, Massachusetts, USA
4Harvard Medical School Center for Palliative Care, Boston, Massachusetts,
USA
5Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
6University of California San Francisco, San Francisco, California, USA
Twitter Follow RACHELLE E. BERNACKI at @rbernack
Contributors SDB is the Director and Principal Investigator of the Serious
Illness Care Program. RB is the Project Director and has been centrally
involved in all aspects of the trial, including the development of the study
protocol. MH is study coordinator and has the primary responsibility of
coordinating development of the study materials, and contributed to the
development of the protocol. JV, GS and JP contributed to the development
of the materials as well as the protocol. SL is the primary biostatistician for
the study. AAG and SDB obtained funds for this trial; AAG also serves as a
senior advisor and co-investigator for the project. All authors reviewed and
approved the manuscript. AAG receives royalties from multiple publishers and
media outlets for essays, books, and films on improvement of healthcare,
including those on end-of-life care.
Funding This work was supported by the Charina Endowment Fund, Partners
Healthcare, and the Margaret T. Morris Foundation. RB is supported by Health
Resources Services Administration grant K01HP2046.
Competing interests None declared.
Ethics approval The study was approved by the Dana-Farber Cancer Institute
Institutional Review Board.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Institute of Medicine. Dying in America: improving quality and
honoring individual preferences near end of life. Washington, DC,
2014.
2. Wright AA, Mack JW, Kritek PA, et al. Influence of patients’
preferences and treatment site on cancer patients’ end-of-life care.
Cancer 2010;116:4656–63.
3. Detering KM, Hancock AD, Reade MC, et al. The impact of advance
care planning on end of life care in elderly patients: randomised
controlled trial. BMJ 2010;340:c1345.
4. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for
patients with metastatic non-small-cell lung cancer. N Engl J Med
2010;363:733–42.
5. Mack JW, Cronin A, Taback N, et al. End-of-life care discussions
among patients with advanced cancer: a cohort study. Ann Intern
Med 2012;156:204–10.
6. Curtis JR, Patrick DL, Caldwell ES, et al. Why don’t patients and
physicians talk about end-of-life care? Barriers to communication for
patients with acquired immunodeficiency syndrome and their primary
care clinicians. Arch Intern Med 2000;160:1690–6.
7. Anderson WG, Chase R, Pantilat SZ, et al. Code status discussions
between attending hospitalist physicians and medical patients at
hospital admission. J Gen Intern Med 2011;26:359–66.
8. Hagerty RG, Butow PN, Ellis PA, et al. Cancer patient preferences
for communication of prognosis in the metastatic setting. J Clin
Oncol 2004;22:1721–30.
9. Smith AK, McCarthy EP, Paulk E, et al. Racial and ethnic
differences in advance care planning among patients with cancer:
impact of terminal illness acknowledgment, religiousness, and
treatment preferences. J Clin Oncol 2008;26:4131–7.
10. Buss MK, Lessen DS, Sullivan AM, et al. Hematology/oncology
fellows’ training in palliative care: results of a national survey. Cancer
2011;117:4304–11.
11. Block SD. Medical education in end-of-life care: the status of reform.
J Palliat Med 2002;5:243–8.
12. Fallowfield L, Jenkins V, Farewell V, et al. Efficacy of a Cancer
Research UK communication skills training model for oncologists:
a randomised controlled trial. Lancet 2002;359:650–6.
13. Back AL, Arnold RM, Baile WF, et al. Faculty development to
change the paradigm of communication skills teaching in oncology.
J Clin Oncol 2009;27:1137–41.
14. Sullivan AM, Lakoma MD, Billings JA, et al. Teaching and learning
end-of-life care: evaluation of a faculty development program in
palliative care. Acad Med 2005;80:657–68.
15. Sullivan AM, Lakoma MD, Billings JA, et al. Creating enduring
change: demonstrating the long-term impact of a faculty
development program in palliative care. J Gen Intern Med
2006;21:907–14.
16. Rao JK, Anderson LA, Inui TS, et al. Communication interventions
make a difference in conversations between physicians and patients:
a systematic review of the evidence. Med Care 2007;45:340–9.
Bernacki R, et al. BMJ Open 2015;5:e009032. doi:10.1136/bmjopen-2015-009032 13
Open Access
17. Fellowes D, Wilkinson S, Moore P. Communication skills training for
health care professionals working with cancer patients, their families
and/or carers. Cochrane Database Syst Rev 2004;(2):CD003751.
18. Jacobsen J, Jackson V, Dahlin C, et al. Components of early
outpatient palliative care consultation in patients with metastatic
nonsmall cell lung cancer. J Palliat Med 2011;14:459–64.
19. Lupu D. Estimate of current hospice and palliative medicine
physician workforce shortage. J Pain Symptom Manage
2010;40:899–911.
20. Block SD, Billings JA. A need for scalable outpatient palliative care
interventions. Lancet 2014;383:1699–700.
21. Bernacki RE, Block SD, American College of Physicians High Value
Care Task Force. Communication about serious illness care goals:
a review and synthesis of best practices. JAMA Intern Med
2014;174:1994–2003.
22. Billings JA, Bernacki R. Strategic targeting of advance care planning
interventions: the Goldilocks phenomenon. JAMA Intern Med
2014;174:620–4.
23. Brach C, Fraser I, Paez K. Crossing the language chasm. Health Aff
(Millwood) 2005;24:424–34.
24. Thornton JD, Pham K, Engelberg RA, et al. Families with limited
English proficiency receive less information and support in
interpreted intensive care unit family conferences. Crit Care Med
2009;37:89–95.
25. Moss AH, Ganjoo J, Sharma S, et al. Utility of the “surprise”
question to identify dialysis patients with high mortality. Clin J Am
Soc Nephrol 2008;3:1379–84.
26. Moss AH, Lunney JR, Culp S, et al. Prognostic significance of the
“surprise” question in cancer patients. J Palliat Med
2010;13:837–40.
27. Curtis JR, Patrick DL, Engelberg RA, et al. A measure of the quality
of dying and death. Initial validation using after-death interviews with
family members. J Pain Symptom Manage 2002;24:17–31.
28. Engelberg RA, Patrick DL, Curtis JR. Correspondence between
patients’ preferences and surrogates’ understandings for dying and
death. J Pain Symptom Manage 2005;30:498–509.
29. Patrick DL, Curtis JR, Engelberg RA, et al. Measuring and improving
the quality of dying and death. Ann Intern Med 2003;139(5 Pt
2):410–15.
30. Kristjanson LJ. Validity and reliability testing of the FAMCARE Scale:
measuring family satisfaction with advanced cancer care. Soc Sci
Med 1993;36:693–701.
31. Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered
important at the end of life by patients, family, physicians, and other
care providers. JAMA 2000;284:2476–82.
32. Steinhauser KE, Clipp EC, McNeilly M, et al. In search of a good
death: observations of patients, families, and providers. Ann Intern
Med 2000;132:825–32.
33. Quill T, Norton S, Shah M, et al. What is most important for you to
achieve? An analysis of patient responses when receiving palliative
care consultation. J Palliat Med 2006;9:382–8.
34. Barnato AE, Llewellyn-Thomas HA, Peters EM, et al.
Communication and decision making in cancer care: setting
research priorities for decision support/patients’ decision aids.
Med Decis Making 2007;27:626–34.
35. Clayton J, Butow P, Tattersall M, et al. Asking questions can help:
development and preliminary evaluation of a question prompt list for
palliative care patients. Br J Cancer 2003;89:2069–77.
36. Mack JW, Weeks JC, Wright AA, et al. End-of-life discussions, goal
attainment, and distress at the end of life: predictors and outcomes
of receipt of care consistent with preferences. J Clin Oncol
2010;28:1203–8.
37. [No authors listed]. A controlled trial to improve care for seriously ill
hospitalized patients. The study to understand prognoses and
preferences for outcomes and risks of treatments (SUPPORT).
The SUPPORT Principal Investigators. JAMA 1995;274:1591–8.
38. Mack JW, Nilsson M, Balboni T, et al. Peace, Equanimity, and
Acceptance in the Cancer Experience (PEACE): validation of a
scale to assess acceptance and struggle with terminal illness.
Cancer 2008;112:2509–17.
39. Cameron IM, Crawford JR, Lawton K, et al. Psychometric
comparison of PHQ-9 and HADS for measuring depression severity
in primary care. Br J Gen Pract 2008;58:32–6.
40. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for
assessing generalized anxiety disorder: the GAD-7. Arch Intern Med
2006;166:1092–7.
41. Martin A, Rief W, Klaiberg A, et al. Validity of the Brief Patient Health
Questionnaire Mood Scale (PHQ-9) in the general population. Gen
Hosp Psychiatry 2006;28:71–7.
42. Mack JW, Block SD, Nilsson M, et al. Measuring therapeutic alliance
between oncologists and patients with advanced cancer: the Human
Connection Scale. Cancer 2009;115:3302–11.
43. Wenrich MD, Curtis JR, Shannon SE, et al. Communicating with
dying patients within the spectrum of medical care from terminal
diagnosis to death. Arch Intern Med 2001;161:868–74.
44. Engelberg R, Downey L, Curtis JR. Psychometric characteristics of a
quality of communication questionnaire assessing communication
about end-of-life care. J Palliat Med 2006;9:1086–98.
45. Ware J Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health
Survey: construction of scales and preliminary tests of reliability and
validity. Med Care 1996;34:220–33.
46. Pargament K, Feuille M, Burdzy D. The brief RCOPE: current
psychometric status of a short measure of religious coping.
Religions 2011;2:51–76.
47. Natarajan S, Lipsitz SR, Fitzmaurice GM, et al. An extension of the
Wilcoxon Rank-Sum test for complex sample survey data. J R Stat
Soc Ser C Appl Stat 2012;61:653–64.
48. Donner A, Klar N. Pitfalls of and controversies in cluster
randomization trials. Am J Public Health 2004;94:416–22.
49. Haybittle JL. Repeated assessment of results in clinical trials of
cancer treatment. Br J Radiol 1971;44:793–7.
50. O’Brien PC, Fleming TR. A multiple testing procedure for clinical
trials. Biometrics 1979;35:549–56.
51. Robins JM, Hernan MA, Brumback B. Marginal structural models
and causal inference in epidemiology. Epidemiology
2000;11:550–60.
14 Bernacki R, et al. BMJ Open 2015;5:e009032. doi:10.1136/bmjopen-2015-009032
Open Access
